Real-World Effectiveness of and Optimization Strategies for Mirikizumab in Pediatric Ulcerative Colitis: A
Keisuke Jimbo1, Nobuyasu Arai1, Mitsuyoshi Suzuki1
1Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
Insights
Mirikizumab (MIRI) effectively induces and sustains clinical remission in pediatric ulcerative colitis (UC). Early optimization strategies, including intestinal ultrasonography, improve treatment outcomes for young patients with UC.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Pharmacology
Background:
- Limited real-world data exists for mirikizumab (MIRI) in pediatric ulcerative colitis (UC).
- Evaluating MIRI's effectiveness, remission patterns, and optimization is crucial for pediatric UC management.
Purpose of the Study:
- To assess the real-world effectiveness of mirikizumab in pediatric UC.
- To analyze remission kinetics and identify optimization strategies for MIRI therapy.
- To explore the role of intestinal ultrasonography in guiding treatment decisions.
Main Methods:
- Prospective cohort study of Japanese children with UC receiving intravenous MIRI followed by subcutaneous maintenance.
- Patients without clinical remission by week 12 received prolonged intravenous induction.
- Outcomes measured included clinical remission (CR), symptomatic remission (SR), ultrasonographic remission (UR), and endoscopic remission (ER).
Main Results:
- Mirikizumab demonstrated significant improvement in all remission measures by week 12 (P < 0.001).
- Durable clinical remission was achieved in 96.4% of patients by week 52.
- Prolonged induction therapy delayed remission but most patients achieved it by week 52; prior biologic exposure did not impact outcomes.
Conclusions:
- Mirikizumab is effective in inducing and sustaining clinical remission in pediatric UC.
- Early optimization strategies, guided by intestinal ultrasonography, enhance MIRI's therapeutic potential.
- Mirikizumab presents a safe, adaptable, and promising treatment option for pediatric UC.
Background:
Real-world evidence for mirikizumab (MIRI) in pediatric ulcerative colitis (UC) is limited. We evaluate the real-world effectiveness, remission kinetics, and optimization strategies for MIRI in pediatric UC.
Methods:
This prospective cohort study included Japanese children with UC receiving intravenous MIRI (300 mg at weeks 0, 4, 8), followed by subcutaneous maintenance (200 mg every 4 weeks). Those without clinical remission (CR; Pediatric Ulcerative Colitis Activity Index [PUCAI] < 10 plus intestinal ultrasonographic [IUS] remission) by week 12 underwent prolonged intravenous induction every 4 weeks until week 24. Outcomes included CR, symptomatic remission (SR), ultrasonographic remission (UR), and endoscopic remission (ER).
Results:
Twenty-eight children were included (median age 13 years; 50% female; median PUCAI 67.5; 67.4% biologics-naive). All remission measures improved by week 12 (P < 0.001). Median time to CR was 10 (interquartile range 4-16) weeks; durable CR occurred in 27/28 (96.4%). From weeks 12 to 52, CR, UR, and ER continued increasing, whereas SR plateaued. Prolonged induction delayed median CR (16 vs 8 weeks) but most patients achieved remission by week 52. On multivariate analysis, prolonged induction was the sole independent predictor of delayed CR, whereas prior biologic exposure was not. Early IUS findings differentiated patients requiring prolonged induction or with prior biologic exposure. No serious adverse events occurred, and MIRI was well tolerated.
Conclusions:
MIRI can induce and sustain CR in pediatric UC, particularly when early optimization strategies are applied. These findings highlight IUS as a useful surrogate for mucosal healing and support MIRI as a promising, adaptable, and safe therapeutic option in pediatric UC.
More Related Videos
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: